Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
vidutolimod (CMP-001)
i
Other names:
CMP-001, CYT003-QbG10, QbG10, CYT 003 QbG10, CYT003, QbG10, allergy vaccine, ARB-1598, Immunodrug CYT003-QbG10, ARB 1598, CMP 001, CYT-003, CYT003 PolQb, CYT003 PolQbeta, virus-like particle-based cancer vaccine
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(3)
News
Trials
Company:
Kuros, Regeneron, Xoma
Drug class:
Immunomodulator, TLR9 agonist
Related drugs:
‹
hydroxychloroquine (7)
quaratusugene ozeplasmid (3)
Orca-T (1)
SQZ-AAC-HPV (1)
SV-102 (1)
MAM-06.301 (1)
ABV-1501 (0)
ALT-801 (0)
ATA520 (0)
HLA-matched donor mononuclear enriched leukocytes (0)
BMS-986242 (0)
CEP-37250 (0)
CK0801 (0)
CO-1002 (0)
CY-101 (0)
rimiducid activated rivogenlecleucel (0)
coprelotamab (0)
GSK2302024A (0)
Ganfule (0)
IL-17E (0)
IMCnyeso (0)
KFA115 (0)
MVA-BN-HER2 (0)
NOV-002 (0)
nelipepimut-S (0)
ORB-011 (0)
engineered donor allograft cell therapy (0)
parvovirus H-1 (0)
FT1050+FT4145 programmed mPB (0)
allodepleted T-cell immunotherapeutics (0)
SER-401 (0)
RB-1355 (0)
ScTIL (0)
ScTIL210 (0)
TAEK-VAC-HerBy vaccine (0)
TAK-012 (0)
TST010 (0)
Undisclosed CISH inactivated TIL (0)
alpha-tocopheroloxyacetic acid (0)
WTX212 (0)
SB-313 (0)
thymalfasin (0)
BAZE-X1 (0)
chlorogenic acid (0)
dendritic cell activation therapy (0)
DVX101 (0)
hV01 (0)
minocycline (0)
EC-18 (0)
HF1K16 (0)
oral rhLF (0)
DV281 (1)
AST-008 (1)
SD-101 (1)
ALTA-002 (0)
GNKG168 (0)
DUET-101 (0)
DUET-201 (0)
ODN2395 (0)
agatolimod (0)
TAC-003 (0)
MGN1703 (0)
TAC-001 (0)
PG545 (0)
IMO-2125 (0)
hydroxychloroquine (7)
quaratusugene ozeplasmid (3)
Orca-T (1)
SQZ-AAC-HPV (1)
SV-102 (1)
MAM-06.301 (1)
ABV-1501 (0)
ALT-801 (0)
ATA520 (0)
HLA-matched donor mononuclear enriched leukocytes (0)
BMS-986242 (0)
CEP-37250 (0)
CK0801 (0)
CO-1002 (0)
CY-101 (0)
rimiducid activated rivogenlecleucel (0)
coprelotamab (0)
GSK2302024A (0)
Ganfule (0)
IL-17E (0)
IMCnyeso (0)
KFA115 (0)
MVA-BN-HER2 (0)
NOV-002 (0)
nelipepimut-S (0)
ORB-011 (0)
engineered donor allograft cell therapy (0)
parvovirus H-1 (0)
FT1050+FT4145 programmed mPB (0)
allodepleted T-cell immunotherapeutics (0)
SER-401 (0)
RB-1355 (0)
ScTIL (0)
ScTIL210 (0)
TAEK-VAC-HerBy vaccine (0)
TAK-012 (0)
TST010 (0)
Undisclosed CISH inactivated TIL (0)
alpha-tocopheroloxyacetic acid (0)
WTX212 (0)
SB-313 (0)
thymalfasin (0)
BAZE-X1 (0)
chlorogenic acid (0)
dendritic cell activation therapy (0)
DVX101 (0)
hV01 (0)
minocycline (0)
EC-18 (0)
HF1K16 (0)
oral rhLF (0)
DV281 (1)
AST-008 (1)
SD-101 (1)
ALTA-002 (0)
GNKG168 (0)
DUET-101 (0)
DUET-201 (0)
ODN2395 (0)
agatolimod (0)
TAC-003 (0)
MGN1703 (0)
TAC-001 (0)
PG545 (0)
IMO-2125 (0)
›
Associations
(3)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Melanoma
No biomarker
Melanoma
nivolumab + CMP-001
Sensitive: B - Late Trials
nivolumab + CMP-001
Sensitive
:
B
nivolumab + CMP-001
Sensitive: B - Late Trials
nivolumab + CMP-001
Sensitive
:
B
No biomarker
Melanoma
No biomarker
Melanoma
pembrolizumab + CMP-001
Sensitive: B - Late Trials
pembrolizumab + CMP-001
Sensitive
:
B
pembrolizumab + CMP-001
Sensitive: B - Late Trials
pembrolizumab + CMP-001
Sensitive
:
B
CD8 positive
Melanoma
CD8 positive
Melanoma
nivolumab + CMP-001
Sensitive: C3 – Early Trials
nivolumab + CMP-001
Sensitive
:
C3
nivolumab + CMP-001
Sensitive: C3 – Early Trials
nivolumab + CMP-001
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.